Specific Factors Influence First-Line Biologic Rx for Psoriasis

This article originally appeared here.
Share this content:
Specific Factors Influence First-Line Biologic Rx for Psoriasis
Specific Factors Influence First-Line Biologic Rx for Psoriasis

WEDNESDAY, April 12, 2017 (HealthDay News) -- The presence of psoriatic arthritis, patient weight, registration country, employment status, and disease severity are the main factors influencing first-line biologic treatment selection for patients with psoriasis, according to a study published online April 7 in the British Journal of Dermatology.

Niall J. Davison, from the University of Manchester in the United Kingdom, and colleagues used data from the British Association of Dermatologists Biologic Interventions Register (January 2012 to December 2015) to determine the factors which influenced the probability of first-line biologic treatment selection for 3,040 individuals with psoriasis.

The researchers found presence of psoriatic arthritis, patient weight, employment status, country of registration, and baseline disease severity were factors affecting first-line biologic selection. Over time, prescribing behavior changed, possibly due to experiences and emerging evidence on treatment effectiveness and safety.

"[This study] provides baseline data to inform the evaluation of future potential changes that may impact prescribing behavior such as stratified medicine," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Higher Fish Intake Appears to Reduce RA Symptoms

Higher Fish Intake Appears to Reduce RA Symptoms

Researchers suggest most varieties of fish may play a role in controlling symptoms

Longer Survival for Midostaurin  Chemotherapy in AML With FLT3

Longer Survival for Midostaurin + Chemotherapy in AML ...

Prolonged overall, event-free survival for patients with acute myeloid leukemia, FLT3 mutation

HIV Testing Inadequate in Young Men Who Have Sex With Men

HIV Testing Inadequate in Young Men Who Have ...

Only 28 percent of young MSM have HIV testing, though they account for 83 percent of new diagnoses

is free, fast, and customized just for you!

Already a member?

Sign In Now »